Clinical trial
A Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma
NCT01302392 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma
- Lead sponsor
- Amgen
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 30, 2010
- Completion date
- September 30, 2015
- Enrollment
- 315 (actual)
- Sites
- 68
Conditions
As the registry lists them; a condition with its own page is linked.